Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Udo Mueller"'
Autor:
Marwan Fakih, Kanwal Pratap Singh Raghav, David Z. Chang, Tim Larson, Allen L. Cohn, Timothy K. Huyck, David Cosgrove, Joseph A. Fiorillo, Rachel Tam, David D'Adamo, Neelesh Sharma, Barbara J. Brennan, Ying A. Wang, Sabine Coppieters, Hong Zebger-Gong, Anke Weispfenning, Henrik Seidel, Bart A. Ploeger, Udo Mueller, Carolina Soares Viana de Oliveira, Andrew Scott Paulson
Publikováno v:
EClinicalMedicine, Vol 58, Iss , Pp 101917- (2023)
Summary: Background: Anti-programmed cell death protein 1 antibodies plus multikinase inhibitors have shown encouraging activity in several tumour types, including colorectal cancer. This study assessed regorafenib plus nivolumab in patients with mic
Externí odkaz:
https://doaj.org/article/607bb200b67a4b90be60f4ef3e49d300
Autor:
Morgan Kruse, Rebecca Wildner, Gisoo Barnes, Monique Martin, Udo Mueller, Francesco Lo-Coco, Ashutosh Pathak
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0134587 (2015)
The objective of this study was to estimate the net cost of arsenic trioxide (ATO) added to all-trans retinoic acid (ATRA) compared to ATRA plus chemotherapy when used in first-line acute promyelocytic leukemia (APL) treatment for low to intermediate
Externí odkaz:
https://doaj.org/article/92f15341f1bd41c6b64db8552990d58c
Autor:
Lynley V. Marshall, Irene Jiménez, Andrew D.J. Pearson, Udo Mueller, Adriaan Cleton, Bart Ploeger, Michael Teufel, Patricia Maeda, Sarah Schlief, Bruce Morland, Andrea C. Agostinho, Gilles Vassal, Jasmine Kincaide, Birgit Geoerger, Didier Frappaz
Publikováno v:
European Journal of Cancer. 153:142-152
Background This phase 1 study evaluated safety, pharmacokinetics (PK), maximum tolerated dose (MTD), and antitumour activity of regorafenib in paediatric patients with solid tumours. Patients and methods Patients (aged 6 months to Results Forty-one p
Autor:
Patrick Liu, Nicole Lang, Ashutosh Pathak, Ruth Pettengell, Udo Mueller, Henry C. Fung, Andreas Lammerich, Ingo Diel, Anton Buchner, Camille N. Abboud, Hartmut Link
Publikováno v:
Supportive Care in Cancer. 27:2569-2577
Recombinant granulocyte colony-stimulating factors (rG-CSFs), such as filgrastim, are administered to prevent complications in patients receiving chemotherapy. In Europe, a biosimilar to filgrastim, tevagrastim/ratiograstim/biograstim, was approved i
Autor:
Agota Szende, Jean Klastersky, Covance, Leeds, United Kingdom, Udo Mueller, Boxiong Tang, Stephen D. Stefani, Jennifer Urwongse, Erika Szabo
Publikováno v:
Jornal Brasileiro de Economia da Saúde. 10:107-117
Autor:
William P. Harris, Max W. Sung, Dirk Waldschmidt, Ying A. Wang, Tatiane Cristine Ishida, Richard D. Kim, Udo Mueller, Barbara J. Brennan, Vittorio Luigi Garosi, Hong Zebger-Gong, Peter R. Galle, Anthony B. El-Khoueiry, Roniel Cabrera
Publikováno v:
Journal of Clinical Oncology. 39:4078-4078
4078 Background: REG, a multikinase inhibitor, and PEMBRO, an anti-PD-1 mAb, are approved as monotherapies in advanced HCC after progression on sorafenib. This phase 1b dose-finding study investigated first-line REG plus PEMBRO in advanced HCC. Metho
Autor:
Richard D. Kim, Dirk Waldschmidt, Flavia Menezes, Tatiane Ishida, Roniel Cabrera, Max W. Sung, Udo Mueller, William P. Harris, Anthony B. El-Khoueiry, Peter R. Galle
Publikováno v:
Journal of Clinical Oncology. 39:323-323
323 Background: In a phase Ib study, REG 120 mg/day plus PEMBRO for first-line treatment of advanced HCC showed no unexpected safety signals and encouraging anti-tumor activity. At the maximum tolerated dose (MTD) of REG (120 mg/day), approximately t
Autor:
Francesco Lo-Coco, Monique Martin, Morgan Kruse, Martin S. Tallman, Gisoo Barnes, Rebecca Wildner, U Udo Mueller, Boxiong Tang
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 15:771-777
This study estimated the cost-effectiveness of arsenic trioxide (ATO) added to all-trans retinoic acid (ATRA) when used in first-line acute promyelocytic leukemia (APL) treatment.A Markov cohort model was developed with 3 states: stable disease (duri
Autor:
Nadège Corradini, Michela Casanova, Hong Zebger-Gong, Arnauld Verschuur, Bart Ploeger, Adela Cañete, Udo Mueller, Lynley V. Marshall, Francisco Bautista, John Chung, Quentin Campbell Hewson, Birgit Geoerger, Guy Makin
Publikováno v:
Journal of Clinical Oncology. 38:10507-10507
10507 Background: In pediatric patients with solid tumors, regorafenib demonstrated acceptable tolerability and preliminary anti-tumor activity. This phase 1 study evaluated regorafenib in combination with vincristine/irinotecan in pediatric patients
Autor:
Omar Tomey, Lee Schwartzberg, Udo Mueller, T Christopher Bond, Boxiong Tang, Susan Gabriel, Erika Szabo, Jean Klastersky
Publikováno v:
Journal of oncology pharmacy practice, 24 (6
Journal of Oncology Pharmacy Practice
Journal of Oncology Pharmacy Practice
Background: Granulocyte colony-stimulating factors are effective at reducing the risk and duration of neutropenia. The current meta-analysis compared the neutropenia-related efficacy and safety of lipegfilgrastim to those of pegfilgrastim and filgras
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdf59780b61929dacef08da8bc9ede2f
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/280444
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/280444